New study aims to unlock the secrets of Children's rare blood diseases

NCT ID NCT04070612

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better understand how these diseases progress and improve future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could identify factors that predict remission, helping doctors tailor treatments for children with these blood disorders.

What could go wrong

This is an observational study, not a treatment trial. It will not test new therapies, and findings may not lead to immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune thrombocytopenic purpura Cytopenia Evans syndrome pancytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HAEMOLYTIC ANAEMIA CYTOPENIA THROMBOCYTOPENIC PURPURA, IMMUNE